Top Stories
Latus Bio raises $97 million Series A to advance MSH3-targeting Huntington's disease gene therapy toward IND filing
Latus Bio disclosed a $97 million Series A financing round, led by 8VC, to advance its lead program LTS-201 — an AAV gene therapy targeting the MSH3 gene — toward IND submission planned for Q3 2026, according to BioPharma Dive. MSH3 drives somatic instability of the CAG repeat expansion in Huntington's disease, representing a mechanistically distinct approach from huntingtin-lowering strategies. Huntington's disease affects approximately 30,000 diagnosed Americans, with a further 200,000 at genetic risk, according to the Huntington's Disease Society of America. The CNS gene therapy space carries well-documented delivery challenges around AAV tropism, immune responses in the brain, and dose-finding. Latus Bio also has a CLN2 disease (Batten disease) program in its pipeline. The company is entering a field where Wave Life Sciences, uniQure, and others have pursued RNA-based and AAV approaches with mixed results, underscoring that Huntington's remains one of the more technically demanding rare CNS targets.
Pipeline Watch
CRISPR Therapeutics reported first quarter 2026 financial results alongside a business update covering its gene editing pipeline, per the company investor relations release. Key programs include CTX001 (exa-cel, approved as Casgevy in sickle cell disease and transfusion-dependent beta-thalassemia) and advancing in vivo CRISPR programs. The quarterly update provides a checkpoint on cash runway and trial enrollment progress across its rare hemoglobin disorder and other indications, according to the CRISPR Therapeutics news release.
The Australian Therapeutic Goods Administration approved Redemplo (plozasiran), an siRNA therapy, for the treatment of familial chylomicronemia syndrome (FCS) on May 1, 2026, according to Pharmaceutical Technology. In the Phase 3 PALISADE trial, plozasiran demonstrated a median 80% reduction in triglycerides and reduced pancreatitis incidence in FCS patients. The drug is administered as a subcutaneous injection every three months. Redemplo also holds FDA approval in the United States, where it received Breakthrough Therapy, Fast Track, and Orphan Drug designations. FCS is an ultra-rare genetic disorder affecting an estimated 1 in 100,000 to 1 in 1,000,000 people.
A BioSpace opinion piece examines the increasing regulatory scrutiny facing gene therapy programs that rely on surrogate biomarkers rather than validated clinical endpoints, as published by BioSpace. The article references REGENXBIO's RGX-121 rejection for Hunter syndrome, where the FDA questioned whether heparan sulfate reduction in cerebrospinal fluid predicts clinical benefit, and the broader pattern of regulatory challenges including BioMarin's Roctavian delays and scrutiny of Sarepta's Elevidys. The piece argues that gene therapy developers must design trials with primary endpoints that demonstrate functional patient benefit rather than relying solely on early biological evidence and external natural history comparators.
Competitive Landscape
Latus Bio's MSH3-targeting gene therapy approach enters a field where RNA-based modalities have advanced further clinically but encountered efficacy and tolerability questions. The competitive differentiation between a one-time gene therapy and chronic RNA-based dosing will hinge on durability of target engagement and CNS delivery safety.
| Company/Program | Modality | Target | Stage | Key Challenge |
|---|---|---|---|---|
| Latus Bio (LTS-201) | Gene Therapy (AAV) | MSH3 | Pre-IND (Q3 2026) | CNS delivery, first-in-class mechanism |
| uniQure (AMT-130) | Gene Therapy (AAV5) | Huntingtin lowering | Phase 1/2 | Long-term durability data pending |
| Wave Life Sciences | RNA Interference | Mutant HTT | Clinical | Allele-selective efficacy consistency |
| Roche-Ionis (tominersen) | Antisense Oligonucleotide | Total HTT | Phase 2 (restarted) | Dose-dependent safety signal |
Recent FDA decisions illustrate an evolving regulatory posture toward gene therapy evidence standards in rare diseases. REGENXBIO's RGX-121 for Hunter syndrome was rejected over biomarker endpoint validity; BioMarin's Roctavian for hemophilia A faced extended review timelines; and Sarepta's Elevidys for Duchenne received scrutiny over its accelerated approval basis. These decisions suggest the agency is requiring clearer links between surrogate biomarkers and functional clinical outcomes for gene therapies.
| Program | Indication | Regulatory Outcome | Evidence Issue |
|---|---|---|---|
| REGENXBIO RGX-121 | Hunter syndrome | CRL (rejected) | CSF biomarker not validated as clinical predictor |
| BioMarin Roctavian | Hemophilia A | Approved (delayed) | Factor VIII durability concerns |
| Sarepta Elevidys | Duchenne MD | Accelerated approval | Dystrophin expression vs. functional benefit |
If Latus Bio advances to approval in Huntington's disease, pricing and outcomes-based contracting would enter territory with limited precedent. Approved CNS gene therapies such as Zolgensma (list price $2.1M, according to Novartis) and Skysona (list price $3M at launch, according to bluebird bio) set reference points, but Huntington's adult-onset profile and larger at-risk population raise distinct payer risk-pooling and durability verification questions compared to pediatric monogenic diseases.
Forward Looking
- Latus Bio IND submission for LTS-201 is planned for Q3 2026; FDA feedback on the MSH3-targeting mechanism and CNS delivery approach will signal regulatory appetite for this novel strategy in Huntington's disease.
- CRISPR Therapeutics commercial Casgevy uptake data from Q1 2026, when disclosed in full, will offer early signals on ex vivo editing patient throughput and payer contracting velocity in sickle cell disease and beta-thalassemia.
- Arrowhead's Redemplo commercial launch trajectory in Australia and continued US post-marketing data in FCS will inform the long-term viability of siRNA-based triglyceride lowering in ultra-rare metabolic conditions.
- The uniQure AMT-130 Phase 1/2 durability readout remains the nearest clinical benchmark for AAV-based approaches in Huntington's disease and will contextualize Latus Bio's differentiated MSH3 mechanism.
